Patents by Inventor Wah Lai

Wah Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250115576
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 10, 2025
    Applicant: Genentech, Inc.
    Inventors: Steven MCKERRALL, Ramsay BEVERIDGE, Kwong Wah LAI, Philippe BERGERON
  • Publication number: 20250042917
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: October 10, 2024
    Publication date: February 6, 2025
    Applicant: Genentech, Inc.
    Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
  • Patent number: 12209075
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. The compounds have sodium channel blocking activity that are useful for treating sodium channel-mediated diseases, in particular for treating pain.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 28, 2025
    Assignee: Genentech, Inc.
    Inventors: Steven McKerrall, Ramsay Beveridge, Kwong Wah Lai, Philippe Bergeron
  • Patent number: 12139496
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
  • Publication number: 20240336625
    Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.
    Type: Application
    Filed: July 15, 2022
    Publication date: October 10, 2024
    Applicant: Genentech, Inc.
    Inventors: Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Craig STIVALA
  • Publication number: 20240239766
    Abstract: The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Z1, Z2, R3-R8, RA, ring A, and n have the meanings described herein, and compositions containing such compounds and methods for using such compounds and compositions for the treatment of pain.
    Type: Application
    Filed: February 22, 2024
    Publication date: July 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Steven John MCKERRALL, Daniel Fred ORTWINE, Philippe BERGERON, Ramsay BEVERIDGE, Elise GHIRO, Kwong Wah LAI, Guqin SHI
  • Publication number: 20240174696
    Abstract: Disclosed are 2,8-diazaspiro[4.5]decane compounds, including (pyrido[3,4-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane compounds, (2,6-naphthyridin-1-yl)-2,8-diazaspiro[4.5]decane compounds, and (1,7-naphthyridin-4-yl)-2,8-diazaspiro[4.5]decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 30, 2024
    Applicant: Genentech, Inc.
    Inventors: Steven John MCKERRALL, Alice Rose WONG, James John CRAWFORD, Wendy LEE, Kwong Wah LAI, Guillaume PELLETIER, Stéphanie ROY, Dana Krystin WINTER, Mikiko OKUMURA, Ruth Dorel
  • Publication number: 20230159555
    Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
    Type: Application
    Filed: July 21, 2022
    Publication date: May 25, 2023
    Applicant: Genentech, Inc.
    Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
  • Publication number: 20220127265
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Publication number: 20220081423
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Application
    Filed: May 26, 2021
    Publication date: March 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI, Zhiguo LIU, Wenfeng LIU, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • Publication number: 20220048888
    Abstract: Described herein are phenoxy-pyridazinyl-pyrimidine or phenoxy-pyrimidinyl-pyrimidine compounds and pharmaceutically acceptable salts thereof for use in the treatment of Ire1-mediated diseases and cancer.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Q. Ly, Joachim Rudolph, Jacob Bradley Schwarz, Avi Ashkenazi, Ramsay Beveridge, Liang Zhao, Alexandre Lemire, Leo Fu, Kwong Wah Lai, Fei Wang
  • Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 11168070
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 9, 2021
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Publication number: 20210253597
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 19, 2021
    Applicant: GENENTECH, INC.
    Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
  • Publication number: 20210214336
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables Y1-Y6, X, Z, Z1, Z2, R2-R3, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2019
    Publication date: July 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Steven MCKERRALL, Ramsay BEVERIDGE, Kwong Wah LAI, Philippe BERGERON
  • Patent number: 11034698
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, James Richard Kiefer, Jr., Jun Liang, Naomi S. Rajapaksa, Yongsheng Chen, Liqiang Fu, Kwong Wah Lai, Zhiguo Liu, John Wai, Fei Wang
  • Publication number: 20210171516
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 24, 2020
    Publication date: June 10, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Philippe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao WANG
  • Patent number: 11028075
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Daniel Sutherlin, Steven McKerrall, Kwong Wah Lai, Zhiguo Liu, Wenfeng Liu, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Publication number: 20210107895
    Abstract: The invention provides a compounds and salts that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI
  • Patent number: 10947251
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 16, 2021
    Assignee: GENENTECH, INC.
    Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai